SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-256532
Filing Date
2023-10-16
Accepted
2023-10-16 08:00:52
Documents
12
Period of Report
2023-10-10
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d760002d8k.htm   iXBRL 8-K 29274
  Complete submission text file 0001193125-23-256532.txt   152914

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aldx-20231010.xsd EX-101.SCH 2851
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20231010_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20231010_pre.xml EX-101.PRE 11262
6 EXTRACTED XBRL INSTANCE DOCUMENT d760002d8k_htm.xml XML 3356
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 231326240
SIC: 2834 Pharmaceutical Preparations